amlodipine besilate / Generic mfg. - LARVOL DELTA

pH-Switchable molecularly imprinted polymers for enantioselective recognition and separation of (S)-amlodipine besylate from its chiral counterpart. (PubMed, Anal Methods) - "Systematic binary competitive experiments with S-ADB and R-ADB at varying molar ratios conclusively established the polymer's excellent enantiomeric discrimination capability, showing minimal interference even when the R-ADB concentration was 4 times higher than that of S-ADB-highlighting its efficacy in addressing the key challenge of chiral separation under competitive conditions. The results demonstrate the promising application of pH-switchable MIPs as a novel platform technology for high-precision chiral resolution and pharmaceutical-grade enantiomer purification."

Journal

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets and Sacubitril Alisartan Calcium Tablets Combined with Amlodipine Besylate Tablets (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Guangzhou Medical University; The Second Affiliated Hospital of Guangzhou Medical University

New trial • Cardiovascular • Hypertension

Coated Zein Polymeric Nanoparticles Loaded with Amlodipine as a Repurposed Antibacterial Ocular Cure for MRSA-Induced Infection: Optimization, In Vitro, Ex Vivo, and In Vivo Assessments. (PubMed, Pharmaceutics) - "Background: Amlodipine besylate (AML) is recognized as a calcium channel blocker curative for hypertension...In vitro microbial assay alongside the corneal in vivo microbial and histological pathology evaluation proved the efficacy of amlodipine as an antibacterial agent. These findings highlighted that the prepared AML-ZNs-Alg eyedrop can be a promising system as an antibacterial therapy."

Journal • Preclinical • Acute Myelogenous Leukemia • Cardiovascular • Hypertension • Infectious Disease

The Development and Characterization of Layered Pellets Containing a Combination of Amorphized Amlodipine Besylate and Hydrochlorothiazide Using a High-Shear Granulator. (PubMed, Pharmaceuticals (Basel)) - "Furthermore, the drug combination in layered pellets was partially amorphized with a lower crystallinity percentage, a lower intensity, a broadening of the hydrochlorothiazide melting peak, and a higher cumulative release of both drugs with good stability, except pellets with a molar ratio of 1:2 that were recrystallized with a higher crystallinity percentage of 79.9%. Modifying the physical form and dissolution behavior of the hydrochlorothiazide and amlodipine besylate combination was achieved by single-step layering pelletization."

Journal

Foamable pluroleosomes system loaded with amlodipine as a repurposed antibacterial topical formulation against MRSA-induced infection; optimization, in-vitro, ex-vivo, and in-vivo studies. (PubMed, Int J Pharm X) - "Amlodipine besylate (AML) is a renowned antihypertensive drug currently acknowledged for having antibacterial activity...In vitro microbiological assay, besides the in vivo microbiological and histopathological studies employing a wound healing model, validated the antibacterial efficacy of amlodipine. Those outcomes demonstrated that the prepared pluroleosome foam system of AML is a competent candidate for combating topical bacterial infection."

Journal • Preclinical • Acute Myelogenous Leukemia • Infectious Disease

Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study. (PubMed, Pharmaceutics) - "In vitro dissolution testing demonstrated pharmaceutical equivalence with the marketed reference FDC, and an in vivo pharmacokinetic study confirmed bioequivalence. These results suggest that the newly developed S-amlodipine besylate-containing FDC tablet is a viable alternative to existing olmesartan/amlodipine/hydrochlorothiazide combinations, offering comparable efficacy and pharmacokinetic properties with the potential for improved safety and patient adherence in the management of hypertension."

Journal • Cardiovascular • Hypertension

Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - "This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP."

Clinical • Journal • Cardiovascular • Hypertension

Antimicrobial Stability, pH, and Physical Appearance of Cardiovascular Drug Suspensions in SyrSpend® SF PH4: A Complementary Evaluation. (PubMed, Int J Pharm Compd) - "Nine oral formulations of seven cardiovascular drug suspensions were included: amlodipine (as besylate) 1.0 mg/mL, enalapril maleate 1.0 mg/mL, hydrochlorothiazide 2.0 and 5.0 mg/mL, lisinopril (as dihydrate) 1.0 mg/mL, metoprolol tartrate 10.0 mg/mL, pentoxifylline 20.0 mg/mL, and spironolactone 2.0 and 2.5 mg/mL. All formulations met USP criteria for antimicrobial effectiveness, while maintaining stable pH values and no relevant changes in physical appearance throughout the study. These results, when combined with previously demonstrated chemical stability (HPLC), confirm that SyrSpend® SF PH4 is a robust and reliable vehicle for preservative-free extemporaneous oral liquid formulations, supporting its safe use within USP-compliant BUD limits."

Journal • Cardiovascular • Pediatrics

Classical and alternative renin-angiotensin-aldosterone systems in a feline remnant kidney model. (PubMed, Am J Vet Res) - "Serum was collected at 2 time points 6 months apart from young-adult purpose-bred cats with remnant kidney model-induced CKD (n = 15; 6 hypertensive, chronically treated with amlodipine besylate) and at a single time point from young-adult community-owned healthy cats (n = 15)...Evidence of RAAS activation at the level of circulating angiotensin peptides was not found in cats with induced CKD. Although circulating aldosterone was increased in cats with induced CKD, this was not likely driven by an increase in other circulating RAAS components."

Journal • Nephrology • Renal Disease

Dual-platform integration of HPTLC and firefly algorithm-optimized chemometrics with hammersley sequence sampling for simultaneous quantification of bisoprolol, amlodipine, and mutagenic impurity 4-hydroxybenzaldehyde. (PubMed, BMC Chem) - "This study presents the first multicolor analytical platform for concurrent determination of bisoprolol fumarate (BIP), amlodipine besylate (AML), and 4-hydroxybenzaldehyde (HBZ), a Class 3 mutagenic impurity in BIP requiring strict regulatory monitoring. Successful application to pharmaceutical dosage forms validated the methods' practical utility. This work establishes a new paradigm in sustainable pharmaceutical analysis, demonstrating how algorithmic optimization and environmental consciousness can synergistically advance analytical science while meeting stringent regulatory requirements."

Journal • Acute Myelogenous Leukemia

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension. (PubMed, J Hum Hypertens) - "After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension."

Journal • Cardiovascular • Hypertension

Spectrophotometric approach for deconvolving overlapped spectra of antihypertensive drug mixtures using UV detection: an eco-friendly method. (PubMed, BMC Chem) - "This study presented four simple, environmentally friendly, chemometric methods for the determination of Amlodipine besylate and Telmisartan, When analyzed together, these drugs exhibit spectral overlapping; therefore, by adopting spectral manipulation, drugs are quantified simultaneously. Using Greenness tools for this UV-spectroscopy method improves both safety and effectiveness compared to expensive and laborious HPLC techniques. Hence, this study suggests employing easy and renewable UV spectrophotometric technologies for traditional analysis."

Journal

Fungal Biodegradation of Amlodipine and Lisinopril by Penicillium citrinum: Towards a Sustainable Approach to Pharmaceutical Wastewater Treatment. (PubMed, Curr Microbiol) - "This study aims to address these concerns by investigating the degradation of most commonly used drugs for hypertension amlodipine besylate and lisinopril, using Penicillium citrinum...The degradation satisfies the first order kinetics model with a higher R2 value of 0.95 and 0.963. The results indicate that the strain was successful in removing amlodipine and lisinopril efficiently."

Journal • Cardiovascular • Hypertension

Prediction of Myasthenia Gravis (MG) Crisis Events by a Machine Learning (ML) Algorithm (ISPOR 2025) - " Patients with MG crises at year 1 (n=332) were significantly ( P <0.05) more likely than those without MG crises at year 1 (n=7277) to be older at MG index date (mean±SD: 61.5±14.5 vs 57.1±14.8 years, respectively), have higher rates of comorbidities/symptoms (eg, shortness of breath [21.1% vs 9.3%], dysphagia [20.0% vs 9.0%]), and have certain prescription claims (eg, albuterol sulfate [11.7% vs 4.9%], amlodipine besylate [11.4% vs 5.6%]). This novel analysis using a ML algorithm identified several key patient-relevant characteristics, disease symptoms, and comorbidities that are risk factors for experiencing an MG crisis, and these results may help inform future treatment strategies to reduce the risk of MG crises."

Machine learning • CNS Disorders • Cough • Gastrointestinal Disorder • Myasthenia Gravis • Pulmonary Disease • Respiratory Diseases

A Green Synchronous Fluorescence Analysis Approach for Simultaneous Determination of the Co-formulated Antihypertensives, Bisoprolol, and Amlodipine. Application to Plasma Samples, Market Formulations, Content Uniformity Test, and Greenness Evaluation. (PubMed, Luminescence) - "In this study, we present a direct, sensitive, and green spectrofluorimetric approach for simultaneous measurement of bisoprolol fumarate (BSL) and amlodipine besylate (AMD) in their tablets and plasma. Besides, BSL is determined in plasma over the range of 0.1-0.5 μg/mL with high percentage recoveries (98.95%-101.60%) and low %RSD values (1.326). The greenness of the developed method was positively assessed using three distinct green metrics, including AGREE, GAPI, and BAGI."

Journal

Stability and Dissolution Behavior Changes After Drug Compounding for Pediatric Cardiovascular Pharmacotherapy. (PubMed, Pharmaceutics) - " Five cardiovascular drugs (amlodipine besylate, carvedilol, propranolol hydrochloride, hydrochlorothiazide, and tadalafil) were selected as target drugs. There was no change in the dissolution rate of the samples after 120 days of storage under each storage condition. The five cardiovascular drugs commonly compounded for children in Japan maintained their pharmaceutical quality after compounding, even after long-term storage."

Journal • Cardiovascular • Pediatrics

Green vibrational spectroscopic approach for simultaneous quantification of antihypertensive drugs in bulk and tablet formulations. (PubMed, Sci Rep) - "An easy, fast, and environmentally friendly FT-IR spectrophotometric method was developed and validated for the simultaneous measurement of amlodipine besylate (AML) and telmisartan (TEL) in pharmaceutical combination formulations. The MoGAPI, AGREE prep, and RGB model assessment procedure was green and sustainable. The described HPLC technique was not significantly different statistically."

Journal • Acute Myelogenous Leukemia

Solubility and thermodynamic properties of amlodipine besylate in two binary mixtures of n-methyl pyrrolidone + 1-propanol/2-propanol at different temperatures. (PubMed, Ann Pharm Fr) - "In this study, the solubility of amlodipine besylate in N-methyl-pyrrolidone/1-propanol and N-methyl-pyrrolidone/2-propanol binary mixture systems were measured using a common shake-flask method followed by spectroscopy analysis at temperature ranges from 298.2 K to 313.2 K. The generated data were fitted to some models, van't Hoff, Jouyban-Acree, Jouyban-Acree-van't Hoff, mixture response surface, and modified Wilson, to mathematical representation the solubility data. Finally, the apparent thermodynamics properties for the saturated mixtures were computed using van't Hoff and Gibbs equations."

Journal

Antihypertensive drug amlodipine besylate shows potential in alleviating diabetic peripheral neuropathy. (PubMed, Diabetes) - "Additionally, AB suppressed the crosstalk between Schwann cells and endothelial cells /DRG neurons in DPN mice. Collectively, our findings highlight the potential of AB for the treatment of DPN."

Journal • Diabetes • Diabetic Neuropathy • Inflammation • Metabolic Disorders • Pain • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • ARRB1 • NLRP3 • STK11

China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT) (clinicaltrials.gov) - P4 | N=32000 | Recruiting | Sponsor: Shenzhen Ausa Pharmed Co.,Ltd | Trial completion date: Jun 2029 ➔ Jun 2030 | Trial primary completion date: Jun 2029 ➔ Jun 2030

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Ischemic stroke • MTHFR

Application of spectrophotometry in novel simultaneous dissolution profiling of a single pill triple therapy of amlodipine, perindopril and indapamide; whiteness evaluation. (PubMed, BMC Chem) - "Simple, diverse univariate spectrophotometric methods were developed and validated for the determination of amlodipine besylate (AM), perindopril arginine (PE), and indapamide (ID). These methods were successfully applied to determine AM, PE, and ID in bulk powder, as well as in Triplixam® tablets, without interference from excipients and in different used dissolution media. The whiteness of the method was evaluated, demonstrating its excellent environmental, analytical and practical efficiency."

Journal

Bioequivalence Study of Single Oral Dose of Allisartan Isoproxil and Amlodipine Besylate Tablets in Healthy Subjects under Fasting Conditions (ChiCTR) - P1 | N=50 | Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Second Affiliated Hospital of Guangzhou Medical University

New P1 trial • Cardiovascular • Hypertension

Novel ecofriendly spectrophotometric methods for the determination of six dihydropyridines calcium channel blockers through derivatization with sulfophtalein dye: application to tablet analysis. (PubMed, BMC Chem) - "Novel, «green» and simple visible spectrophotometric procedures for the determination of six dihydropyridines CCBs (amlodipine besylate (AML), lacidipine (LAC), levamlodipine besylate (LAML), nifedipine (NIF), nimodipine (NIM) and nitrendipine (NIT)) through derivatization with the sulfophthalein dye bromophenol blue (BPB) have been developed. The developed methods are colorimetric and therefore does not require a UV instrument to quantify these drugs. The proposed approach was more efficient in terms of time reliability, sensitivity and «greenness» than other recorded spectrophotometric methods and can be easily implemented for routine pharmaceutical analysis."

Journal • Acute Myelogenous Leukemia

Morning Versus Bedtime Dosing of Antihypertensive Medication (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Yan Li | Trial completion date: Jan 2023 ➔ Sep 2026 | Trial primary completion date: Jan 2023 ➔ Jun 2026

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

Modeling craniopharyngioma for drug screening reveals a neuronal mechanism for tumor growth. (PubMed, Sci Transl Med) - "The administration of (S)-amlodipine besylate achieved tumor regression in vivo, potentially by abrogating calcium transients and neuron-to-tumor chemical transmission. Chemogenetic manipulation of neuroendocrine neuronal activity bidirectionally regulated tumor cell growth in our mouse model, suggesting that craniopharyngioma hijacks hypothalamic neurons to promote tumor progression. These findings deepen our understanding of suprasellar tumor biology and offer promising avenues for clinical exploration of effective chemotherapies."

Journal • Preclinical • Brain Cancer • CNS Tumor • Metabolic Disorders • Oncology